IL18 and cancer: In short, the OS and DFS results show that high NLRP3 inflammasome expression (NLRP3/IL-18/ IL-1β/ASC) in LSCC cancer tissues forecasts a poor outcome compared to low NLRP3 inflammasome expression (NLRP3/IL-18/IL-1β/ASC) in cancer tissues (Figure 5, P < 0.05).